Terms: = Kidney tumors AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Treatment
733 results:
1. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma.
Rahman SN; Long JB; Westvold SJ; Leapman MS; Spees LP; Hurwitz ME; McManus HD; Gross CP; Wheeler SB; Dinan MA
JAMA Netw Open; 2024 Apr; 7(4):e248747. PubMed ID: 38687479
[TBL] [Abstract] [Full Text] [Related]
2. Management of Nontraumatic Spontaneous Renal Hemorrhage (Wünderlich Syndrome) through Robotic-Assisted Laparoscopic Nephrectomy: A Case Series.
Tao B; Zhang H; Zhang G; Liu H; Meng L; Zhu X; Ji X; Jia G; Qi A; Wang C
Am J Case Rep; 2024 Apr; 25():e942826. PubMed ID: 38659203
[TBL] [Abstract] [Full Text] [Related]
3. The impact of the COVID-19 pandemic on renal cancer care.
Yildirim H; Bins AD; van den Hurk C; van Moorselaar RJA; van Oijen MGH; Bex A; Zondervan PJ; Aben KKH
World J Urol; 2024 Apr; 42(1):231. PubMed ID: 38613582
[TBL] [Abstract] [Full Text] [Related]
4. Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study.
Eigler C; McDougall L; Bauman A; Bernhardt P; Hentschel M; Blackham KA; Nicolas G; Fani M; Wild D; Cordier D
J Nucl Med; 2024 Apr; 65(4):573-579. PubMed ID: 38423782
[TBL] [Abstract] [Full Text] [Related]
5. Percutaneous Microwave Ablation for treatment of Retroperitoneal tumors.
Rossebo AE; Zlevor AM; Knott EA; Mao L; Couillard AB; Ziemlewicz TJ; Hinshaw JL; Abel EJ; Lubner MG; Knavel Koepsel EM; Wells SA; Stratchko LM; Laeseke PF; Lee FT
Radiol Imaging Cancer; 2024 Mar; 6(2):e230080. PubMed ID: 38334471
[TBL] [Abstract] [Full Text] [Related]
6. All-Cause and Cause-Specific Mortality Among Low-Risk Differentiated Thyroid Cancer Survivors in the United States.
Tran TV; Schonfeld SJ; Pasqual E; Haymart MR; Morton LM; Kitahara CM
Thyroid; 2024 Feb; 34(2):215-224. PubMed ID: 38149602
[No Abstract] [Full Text] [Related]
7. treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy.
Hahn AW; Surasi DS; Viscuse PV; Bathala TK; Wiele AJ; Campbell MT; Zurita AJ; Shah AY; Jonasch E; Gao J; Goswami S; Alhalabi O; Rao P; Sircar K; Tannir NM; Msaouel P
Oncologist; 2024 May; 29(5):392-399. PubMed ID: 38035767
[TBL] [Abstract] [Full Text] [Related]
8. Celastrol enhances TRAIL‑R2‑mediated apoptosis and cytotoxicity in human renal cell carcinoma cells in caspase‑dependent manner.
Bao Y; Wu X; Kanematsu A; Kita Y; Kobayashi T; Kakehi Y; Yamamoto S
Oncol Rep; 2024 Jan; 51(1):. PubMed ID: 37997857
[TBL] [Abstract] [Full Text] [Related]
9. Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [
Günther T; Holzleitner N; Viering O; Beck R; Wienand G; Dierks A; Pfob CH; Bundschuh RA; Kircher M; Lapa C; Wester HJ
J Nucl Med; 2024 Jan; 65(1):33-39. PubMed ID: 37945383
[TBL] [Abstract] [Full Text] [Related]
10. treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: A report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS-5.
Benedetti DJ; Varela CR; Renfro LA; Tornwall B; Dix DB; Ehrlich PF; Glick RD; Kalapurakal J; Perlman E; Gratias E; Seibel NL; Geller JI; Khanna G; Malogolowkin M; Grundy P; Fernandez CV; Dome JS; Mullen EA
Cancer; 2024 Mar; 130(6):947-961. PubMed ID: 37933882
[TBL] [Abstract] [Full Text] [Related]
11. Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial.
Kowdley KV; Modi NB; Peltekian K; Vierling JM; Ferris C; Valone FH; Gupta S
Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1118-1128. PubMed ID: 37863080
[TBL] [Abstract] [Full Text] [Related]
12. Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid Cancer Treated With VEGFR TKIs.
Narayan V; Liu T; Song Y; Mitchell J; Sicks J; Gareen I; Sun L; Denduluri S; Fisher C; Manikowski J; Wojtowicz M; Vadakara J; Haas N; Margulies KB; Ky B
J Natl Compr Canc Netw; 2023 Oct; 21(10):1039-1049.e10. PubMed ID: 37856199
[TBL] [Abstract] [Full Text] [Related]
13. [Factors influencing the chronic post-surgical pain after laparoscopic surgery for elderly patients with urinary tract tumors].
Liu HL; Lv YH; Wang XX; Li M
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 55(5):851-856. PubMed ID: 37807739
[TBL] [Abstract] [Full Text] [Related]
14. Predictive factors and prognosis of upper gastrointestinal bleeding in gastric cancer: A large population-based study (UGIB-GC trial).
Kiattiweerasak A; Bongkotvirawan P; Aumpan N; Yamaoka Y; Miftahussurur M; Vilaichone RK
PLoS One; 2023; 18(9):e0291926. PubMed ID: 37729185
[TBL] [Abstract] [Full Text] [Related]
15. CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (
Grand-Guillaume J; Mansi R; Gaonkar RH; Zanger S; Fani M; Eugster PJ; Beck Popovic M; Grouzmann E; Abid K
J Transl Med; 2023 Sep; 21(1):604. PubMed ID: 37679770
[TBL] [Abstract] [Full Text] [Related]
16. RECIST 1.1 Target Lesion Categorical Response in Metastatic Renal Cell Carcinoma: A Comparison of Conventional versus Volumetric Assessment.
Gong AJ; Ruchalski K; Kim HJ; Douek M; Gutierrez A; Patel M; Sai V; Coy H; Villegas B; Raman S; Goldin J
Radiol Imaging Cancer; 2023 Sep; 5(5):e220166. PubMed ID: 37656041
[TBL] [Abstract] [Full Text] [Related]
17. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary tumors.
El Zarif T; Nassar AH; Pond GR; Zhuang TZ; Master V; Nazha B; Niglio S; Simon N; Hahn AW; Pettaway CA; Tu SM; Abdel-Wahab N; Velev M; Flippot R; Buti S; Maruzzo M; Mittra A; Gheeya J; Yang Y; Rodriguez PA; Castellano D; de Velasco G; Roviello G; Antonuzzo L; McKay RR; Vincenzi B; Cortellini A; Hui G; Drakaki A; Glover M; Khaki AR; El-Am E; Adra N; Mouhieddine TH; Patel V; Piedra A; Gernone A; Davis NB; Matthews H; Harrison MR; Kanesvaran R; Giudice GC; Barata P; Farolfi A; Lee JL; Milowsky MI; Stahlfeld C; Appleman L; Kim JW; Freeman D; Choueiri TK; Spiess PE; Necchi A; Apolo AB; Sonpavde GP
J Natl Cancer Inst; 2023 Dec; 115(12):1605-1615. PubMed ID: 37563779
[TBL] [Abstract] [Full Text] [Related]
18. Race and treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial.
Sayegh N; Swami U; Jo Y; Gebrael G; Haaland B; Gupta S; Plets M; Hussain MHA; Quinn DI; Lara PN; Thompson IM; Agarwal N
JAMA Netw Open; 2023 Aug; 6(8):e2326546. PubMed ID: 37526936
[TBL] [Abstract] [Full Text] [Related]
19. Early tumor-related hemorrhage after stereotactic radiosurgery of brain metastases: Systematic review of reported cases.
Maarif R; Kubota Y; Chernov MF
J Clin Neurosci; 2023 Sep; 115():66-70. PubMed ID: 37499321
[TBL] [Abstract] [Full Text] [Related]
20. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.
Albiges L; Gurney H; Atduev V; Suarez C; Climent MA; Pook D; Tomczak P; Barthelemy P; Lee JL; Stus V; Ferguson T; Wiechno P; Gokmen E; Lacombe L; Gedye C; Perini RF; Sharma M; Peng X; Lee CH
Lancet Oncol; 2023 Aug; 24(8):881-891. PubMed ID: 37451291
[TBL] [Abstract] [Full Text] [Related]
[Next]
